A complication of the Infusaid pump: duodenal atony reversed by urecholine.
The totally implantable infusion pump (Infusaid pump) for treating metastatic disease to the liver is a new treatment that is gaining widespread acceptance. However, as might be expected for any new major surgical procedure, there are increasing reports of complications. We report a complication in which duodenal atony was caused by the infusion of the chemotherapeutic agent (FUDR) into the stomach and duodenum. The atony was totally reversed by the subcutaneous administration of urecholine.
D001626:Bethanechol Compounds / Q000627:therapeutic use*; D004380:Duodenal Obstruction / Q000188:drug therapy / Q000209:etiology*; D004386:Duodenum / Q000473:pathology / Q000503:physiopathology; D005467:Floxuridine / Q000008:administration & dosage / Q000009:adverse effects; D005769:Gastrointestinal Motility; D006801:Humans; D007260:Infusion Pumps / Q000009:adverse effects*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D000267:Tissue Adhesions / Q000209:etiology / Q000473:pathology
D001626:Bethanechol Compounds; D005467:Floxuridine